Home › Aortic Valve Stenosis › California › Los Angeles
Aortic Valve Stenosis clinical trials in Los Angeles, CA
6 studies for Aortic Valve Stenosis are looking for participants at sites in and around Los Angeles (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve
Recruiting
- Cedars-Sinai Medical Center, Los Angeles
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
RecruitingObservational study
- Kaiser Permanente Los Angeles Medical Center, Los Angeles
Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
RecruitingPhase 2/3
- UCLA Ronald Reagan Medical Center, Los Angeles
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
Recruiting
- Cedars-Sinai Medical Center, Los Angeles
Bicuspid Aortic Valve Replacement: Evaluation of Transcatheter Versus Surgery-Pilot Trial
Recruiting
- Cedars-Sinai Medical Center, Los Angeles
PARTNER 3 Trial - Aortic Valve-in-Valve
Recruiting
- University of California Los Angeles, Los Angeles
Aortic Valve Stenosis trials in other cities
- Boston, MA10 studies
- San Francisco, CA9 studies
- New York City, NY9 studies
- Cleveland, OH8 studies
- Cincinnati, OH7 studies
- Houston, TX7 studies
- Mountain View, CA7 studies
- Pittsburgh, PA6 studies
- Plano, TX6 studies
- Rochester, MN6 studies
- Chicago, IL6 studies
- Newark, NJ6 studies
Other studies in Los Angeles
- Non-Small Cell Lung Cancer87 studies
- Cancer (all types)74 studies
- Breast Cancer73 studies
- Prostate Cancer61 studies
- Colorectal Cancer59 studies
- Metastatic Cancer57 studies
- Ovarian Cancer50 studies
- Lung Cancer45 studies
- Head and Neck Squamous Cell Carcinoma42 studies
- Pancreatic Cancer35 studies
- Endometrial Cancer34 studies
- Melanoma34 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.